Cargando…

1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE

Detalles Bibliográficos
Autores principales:	Xu, Alexander, Li, Dalin, Elyanow, Rebecca, Gittelman, Rachel M., Chapman, Heidi, Prostko, John, Pozdnyakova, Valeriya, Debbas, Philip, Mujukian, Angela, Horizon, Arash A., Sobhani, Kimia, Cheng, Susan, Kaplan, Ian M., Mcgovern, Dermot P.B., Merchant, Akil, Melmed, Gil, Braun, Jonathan G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212302/ http://dx.doi.org/10.1016/S0016-5085(22)60659-0

Ejemplares similares

Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY
por: Li, Dalin, et al.
Publicado: (2022)

Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease
por: Xu, Alexander M., et al.
Publicado: (2022)

The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders
por: Li, Dalin, et al.
Publicado: (2021)

The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy
por: Li, Dalin, et al.
Publicado: (2022)

653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION
por: Li, Dalin, et al.
Publicado: (2022)

656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Mujukian, Angela, et al.
Publicado: (2022)

Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD
por: Li, Dalin, et al.
Publicado: (2022)

Post-Vaccination Symptoms after A Third Dose of mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease
por: Li, Dalin, et al.
Publicado: (2021)

Tu1544: HUMORAL AND T CELL RESPONSES TO COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022)

Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kappelman, Michael, et al.
Publicado: (2022)

Fr105 CONTINUITY OF CARE FOR PATIENTS WITH CHRONIC GASTROINTESTINAL DISEASE: A LATENT CLASS ANALYSIS OF PATIENTS WITH HIGH-INTENSITY SPECIALTY CARE NEEDS
por: Cohen-Mekelburg, Shirley, et al.
Publicado: (2021)

Tu1548: IMMUNE RESPONSE AFTER COVID-19 VACCINATION DURING MAINTANACE THERAPY IN IMMUNE-MEDIATED INFLAMMATORY DISEASES: AN OBSERVATIONAL COHORT STUDY
por: Dayam, R.M., et al.
Publicado: (2022)

94: ANTIBODY RESPONSE AFTER A BOOSTER DOSE OF SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS AND THOSE WITH CHRONIC LIVER DISEASES
por: Chauhan, Mahak, et al.
Publicado: (2022)

Su1494: REDUCED SEROLOGICAL RESPONSE TO COVID-19 VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; EARLY RESULTS OF THE VARIATION STUDY (VARIABILITY IN RESPONSE IN IBD AGAINST SARS-COV2-IMMUNISATION)
por: Doherty, Jayne, et al.
Publicado: (2022)

Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION
por: Alexander, James L., et al.
Publicado: (2022)

Tu1546: JAPAN PROSPECTIVE MULTICENTER STUDY FOR OPTIMIZATION OF COVID-19 VACCINATIONS BASED ON THE IMMUNE RESPONSE AND SAFETY PROFILE IN INFLAMMATORY BOWEL DISEASE PATIENTS: INTERIM ANALYSES
por: Watanabe, Kenji, et al.
Publicado: (2022)

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease
por: Pozdnyakova, VALERIYA, et al.
Publicado: (2021)

Sa1050: COVID-19 VACCINATION RATES AND POST-VACCINATION INFECTION RISK IN IBD PATIENTS TREATED WITH DISEASE MODIFYING AGENTS: A RESEARCH NETWORK ANALYSIS
por: Chumbe, Julton Tomanguillo, et al.
Publicado: (2022)

Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES
por: Rabinowitz, Keren M., et al.
Publicado: (2022)

654: A THIRD DOSE OF SARS-COV-2 VACCINE YIELDS HIGH ANTIBODY LEVELS COMPARED TO TWO DOSE VACCINATION SCHEDULE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Quan, Joshua, et al.
Publicado: (2022)

EP1270: SEROCONVERSION IN INFLAMMATORY BOWEL DISEASE PATIENTS AFTER COVID-19 VACCINATION
por: Horvath, Miklos, et al.
Publicado: (2022)

Su1495: COVID-19 VACCINE HESITANCY REMAINS HIGH IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Kwon, Hyuk Joon, et al.
Publicado: (2022)

Su1491: ATTITUDES AND PREDICTORS OF COVID-19 VACCINE UPTAKE IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Su1498: SAFETY OF COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY
por: Garrido, Isabel, et al.
Publicado: (2022)

Su1003: IMPACT OF THE COVID-19 PANDEMIC ON HEALTHCARE ACCESS, DELIVERY AND VACCINATION IN PATIENTS WITH DIGESTIVE DISORDERS
por: Russin, Michelle, et al.
Publicado: (2022)

AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update
por: Sultan, Shahnaz, et al.
Publicado: (2021)

Tu1547: COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Meybodi, Mohamad Aghaie, et al.
Publicado: (2022)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

Mo1020: GUT MICROBIOME CHANGES ASSOCIATED WITH HIGHER AND LONGER-LASTING ANTIBODY TITERS FOLLOWING COVID-19 VACCINATION
por: Venzon, Mericien M., et al.
Publicado: (2022)

Sa1063: COVID AND COVID VACCINATION AMONG OUTPATIENTS WITH FUNCTIONAL GI AND GI MOTILITY DISORDERS; EFFECTS ON GI SYMPTOMS.
por: Silver, Paul, et al.
Publicado: (2022)

Su1497: EFFECT OF SARS COV-2 VACCINE IN IBD PATIENTS ON BIOLOGIC THERAPY INCLUDING LIVER TRANSPLANT RECIPIENTS.
por: Brezina, Jan, et al.
Publicado: (2022)

Tu1550: REAL WORLD USE AND ADVERSE EVENTS OF SARS-COV-2 VACCINATION IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Orfanoudaki, Eleni, et al.
Publicado: (2022)

Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES
por: Boland, Brigid S., et al.
Publicado: (2022)

A Paratope-Enhanced Method to Determine Breadth and Depth TCR Clonal Metrics of the Private Human T-Cell Vaccine Response after SARS-CoV-2 Vaccination
por: Li, Dalin, et al.
Publicado: (2023)

Tu1549: IMPLEMENTATION AND SHORT-TERM ADVERSE EVENTS OF ANTI-SARSCOV-2 VACCINES IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTERNATIONAL WEB-BASED SURVEY
por: Revés, Joana, et al.
Publicado: (2022)

Sa1271: PATIENTS WITH CELIAC DISEASE HAVE NO INCREASED RATE OF ADVERSE EVENTS AFTER COVID-19 VACCINE ADMINISTRATION COMPARED WITH NON-CELIAC CONTROLS
por: Russell, Lindsey, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qkvde62felctr132onbde8837i